JAMA study confirms drug can help improve memory and cognition in advanced Alzheimer's patients

January 20, 2004

A study in the current issue of the Journal of the American Medical Association (JAMA) indicates that there is good reason for the recent attention surrounding the drug memantine for the treatment of Alzheimer's disease. A multi-center study directed by University of Rochester Medical Center faculty concluded that memantine, when taken with the commonly prescribed Alzheimer's drug donepezil, helped moderate to severe Alzheimer's patients maintain or in some cases, improve their memory and other intellectual functions, and helped to preserve activities of daily living during the study period. This represents the first medication approved by the FDA to treat advanced Alzheimer's patients, as well as a new category of medication to treat the disease.

Lead investigator Pierre N. Tariot, M.D., professor of psychiatry at the University of Rochester Medical Center, said that the study was significant not only because it validates a new class of drugs for the treatment of Alzheimer's, but also because it was the first time positive results have been seen combining two Alzheimer's drugs.

"To find a new medication that can provide substantial benefit to patients at this stage of the disease, either alone or in combination with another Alzheimer's drug, is certainly good news," Tariot said.

Thirty-seven institutions participated in the study between June 11, 2001 and June 3, 2002. The study compared the efficacy and safety of memantine versus placebo (sugar pill) in patients with moderate to severe AD already taking the cholinesterase inhibitor, donepezil. A total of 404 patients were enrolled, and 322 patients (80 percent) completed the clinical trial.

According to Tariot, patients who took the memantine and donepezil versus those on placebo showed statistically significant improvement in cognition, memory, and overall daily functioning.

"Family members tended to say things like, 'Gee, he's more like himself; he participates in and can follow a conversation; he can talk on the phone; he does not get as upset.' Or, 'He doesn't appear to be declining the way he did before,'" Tariot added. "While memantine is not a cure for Alzheimer's, if it helps to keep a person with Alzheimer's at home for six months or one year longer, then it is a victory."

The two medications target two separate cell mechanisms. Memantine is known as a "low to moderate affinity NMDA receptor antagonist," which overstimulates glutamate, a brain chemical implicated in nerve cell death when produced in high quantities. On the other hand, donepezil is an "acetylcholinesterase inhibitor," and works by preventing the break down of acetylcholine, a chemical messenger in the brain that is important for memory and other thinking skills. Before the FDA approved memantine in October 2003, the only medications approved for Alzheimer's treatments were all acetylcholinesterase inhibitors.

"We were pleasantly surprised to see that the two drugs worked well together," Tariot said. "Memantine is significant, since it provides an entirely new medication option for the 2.5 million people currently suffering at the advanced stage of Alzheimer's."

Today, more than 4.5 million Americans suffer with Alzheimer's, a progressive disease of the brain that is the most common type of dementia (a term used to describe the progressive loss of cognitive, intellectual or functional abilities). That number is expected to quadruple by 2050. Of those currently living with Alzheimer's disease, half are in the moderate to severe stages.
-end-


University of Rochester Medical Center

Related Memory Articles from Brightsurf:

Memory of the Venus flytrap
In a study to be published in Nature Plants, a graduate student Mr.

Memory protein
When UC Santa Barbara materials scientist Omar Saleh and graduate student Ian Morgan sought to understand the mechanical behaviors of disordered proteins in the lab, they expected that after being stretched, one particular model protein would snap back instantaneously, like a rubber band.

Previously claimed memory boosting font 'Sans Forgetica' does not actually boost memory
It was previously claimed that the font Sans Forgetica could enhance people's memory for information, however researchers from the University of Warwick and the University of Waikato, New Zealand, have found after carrying out numerous experiments that the font does not enhance memory.

Memory boost with just one look
HRL Laboratories, LLC, researchers have published results showing that targeted transcranial electrical stimulation during slow-wave sleep can improve metamemories of specific episodes by 20% after only one viewing of the episode, compared to controls.

VR is not suited to visual memory?!
Toyohashi university of technology researcher and a research team at Tokyo Denki University have found that virtual reality (VR) may interfere with visual memory.

The genetic signature of memory
Despite their importance in memory, the human cortex and subcortex display a distinct collection of 'gene signatures.' The work recently published in eNeuro increases our understanding of how the brain creates memories and identifies potential genes for further investigation.

How long does memory last? For shape memory alloys, the longer the better
Scientists captured live action details of the phase transitions of shape memory alloys, giving them a better idea how to improve their properties for applications.

A NEAT discovery about memory
UAB researchers say over expression of NEAT1, an noncoding RNA, appears to diminish the ability of older brains to form memories.

Molecular memory can be used to increase the memory capacity of hard disks
Researchers at the University of Jyväskylä have taken part in an international British-Finnish-Chinese collaboration where the first molecule capable of remembering the direction of a magnetic above liquid nitrogen temperatures has been prepared and characterized.

Memory transferred between snails
Memories can be transferred between organisms by extracting ribonucleic acid (RNA) from a trained animal and injecting it into an untrained animal, as demonstrated in a study of sea snails published in eNeuro.

Read More: Memory News and Memory Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.